News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
465,224 Results
Type
Article (24692)
Company Profile (148)
Press Release (440375)
Multimedia
Podcasts (39)
Webinars (13)
Section
Business (123857)
Career Advice (448)
Deals (20375)
Drug Delivery (44)
Drug Development (79293)
Employer Resources (47)
FDA (12641)
Job Trends (9311)
News (233345)
Policy (18673)
Tag
Academia (1688)
Academic (1)
Accelerated approval (14)
Adcomms (29)
Allergies (108)
Alliances (33751)
ALS (134)
Alzheimer's disease (1508)
Antibody-drug conjugate (ADC) (180)
Approvals (12738)
Artificial intelligence (338)
Autoimmune disease (54)
Automation (15)
Bankruptcy (146)
Best Places to Work (8156)
BIOSECURE Act (12)
Biosimilars (97)
Biotechnology (115)
Bladder cancer (112)
Brain cancer (43)
Breast cancer (429)
Cancer (3369)
Cardiovascular disease (271)
Career advice (397)
Career pathing (15)
CAR-T (207)
CDC (10)
Cell therapy (537)
Cervical cancer (31)
Clinical research (67507)
Collaboration (1050)
Company closure (3)
Compensation (657)
Complete response letters (33)
COVID-19 (2102)
CRISPR (58)
C-suite (434)
Cystic fibrosis (113)
Data (3929)
Decentralized trials (2)
Denatured (18)
Depression (91)
Diabetes (346)
Diagnostics (5259)
Digital health (25)
Diversity (9)
Diversity, equity & inclusion (18)
Drug discovery (141)
Drug pricing (34)
Drug shortages (12)
Duchenne muscular dystrophy (159)
Earnings (49202)
Editorial (21)
Employer branding (3)
Employer resources (45)
Events (75285)
Executive appointments (754)
FDA (14677)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (5)
Frontotemporal dementia (11)
Funding (948)
Gene editing (127)
Generative AI (27)
Gene therapy (400)
GLP-1 (636)
Government (2315)
Grass and pollen (5)
Guidances (255)
Healthcare (13759)
HIV (36)
Huntington's disease (35)
IgA nephropathy (52)
Immunology and inflammation (170)
Immuno-oncology (10)
Indications (50)
Infectious disease (2263)
Inflammatory bowel disease (168)
Inflation Reduction Act (3)
Influenza (71)
Intellectual property (146)
Interviews (63)
IPO (10986)
IRA (13)
Job creations (1494)
Job search strategy (352)
Kidney cancer (14)
Labor market (27)
Layoffs (312)
Leadership (11)
Legal (2295)
Liver cancer (75)
Longevity (11)
Lung cancer (487)
Lymphoma (236)
Machine learning (19)
Management (15)
Manufacturing (344)
MASH (113)
Medical device (9393)
Medtech (9408)
Mergers & acquisitions (10084)
Metabolic disorders (801)
Multiple sclerosis (121)
NASH (14)
Neurodegenerative disease (182)
Neuropsychiatric disorders (39)
Neuroscience (2360)
NextGen: Class of 2025 (3872)
Non-profit (2415)
Now hiring (30)
Obesity (335)
Opinion (158)
Ovarian cancer (114)
Pain (135)
Pancreatic cancer (153)
Parkinson's disease (213)
Partnered (17)
Patents (300)
Patient recruitment (290)
Peanut (49)
People (38146)
Pharmaceutical (35)
Pharmacy benefit managers (3)
Phase I (21715)
Phase II (30098)
Phase III (21742)
Pipeline (2295)
Policy (83)
Postmarket research (2054)
Preclinical (7843)
Press Release (28)
Prostate cancer (165)
Psychedelics (36)
Radiopharmaceuticals (253)
Rare diseases (504)
Real estate (2901)
Recruiting (18)
Regulatory (16747)
Reports (26)
Research institute (1848)
Resumes & cover letters (60)
Rett syndrome (12)
RNA editing (9)
RSV (37)
Schizophrenia (108)
Series A (167)
Series B (134)
Service/supplier (8)
Sickle cell disease (60)
Special edition (13)
Spinal muscular atrophy (144)
Sponsored (22)
Startups (2399)
State (1)
Stomach cancer (13)
Supply chain (45)
Tariffs (14)
The Weekly (21)
Vaccines (611)
Venture capital (35)
Weight loss (188)
Women's health (45)
Worklife (6)
Date
Today (77)
Last 7 days (450)
Last 30 days (1856)
Last 365 days (26042)
2025 (19441)
2024 (29267)
2023 (33137)
2022 (41037)
2021 (42996)
2020 (39541)
2019 (30537)
2018 (22975)
2017 (23791)
2016 (21719)
2015 (25418)
2014 (18377)
2013 (13800)
2012 (14435)
2011 (14808)
2010 (13946)
Location
Africa (366)
Alabama (61)
Alaska (3)
Arizona (139)
Arkansas (8)
Asia (28382)
Australia (5526)
California (7682)
Canada (2076)
China (733)
Colorado (308)
Connecticut (319)
Delaware (195)
Europe (64974)
Florida (1059)
Georgia (249)
Hawaii (1)
Idaho (40)
Illinois (456)
India (26)
Indiana (322)
Iowa (13)
Japan (255)
Kansas (89)
Kentucky (28)
Louisiana (10)
Maine (25)
Maryland (872)
Massachusetts (5541)
Michigan (161)
Minnesota (332)
Mississippi (3)
Missouri (76)
Montana (28)
Nebraska (16)
Nevada (83)
New Hampshire (55)
New Jersey (1990)
New Mexico (22)
New York (2077)
North Carolina (1013)
North Dakota (6)
Northern California (3550)
Ohio (204)
Oklahoma (17)
Oregon (31)
Pennsylvania (1555)
Puerto Rico (12)
Rhode Island (22)
South America (482)
South Carolina (28)
Southern California (3011)
Tennessee (107)
Texas (1217)
United States (26705)
Utah (202)
Virginia (178)
Washington D.C. (51)
Washington State (617)
West Virginia (2)
Wisconsin (57)
Wyoming (1)
465,224 Results for "quotient clinical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Quotient Therapeutics Appoints Drug Discovery and Development Veteran, Andrew Bayliffe, as Chief Development Officer
September 30, 2025
·
2 min read
Collaboration
Pfizer Partners With Flagship’s Quotient to Leverage Genetics Against Heart, Renal Diseases
Quotient Therapeutics’ platform targets somatic mutations, which the startup contends can help identify a broader scope of genes potentially associated with disease phenotypes. Wednesday’s agreement is part of an existing partnership between Pfizer and Flagship Pioneering.
August 28, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Quotient Therapeutics Appoints Sir Mene Pangalos, Ph.D. to Board of Directors
November 8, 2024
·
3 min read
Press Releases
Quotient Therapeutics Appoints Peter Campbell, Ph.D. as Chief Scientific Officer
August 7, 2024
·
2 min read
Press Releases
Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer
August 28, 2024
·
4 min read
Press Releases
Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Conce
- Funding combines equity investment and convertible loan - Focus on best-in-class, clinical-stage peanut allergen neutralizing antibody - Further potential for developing Mabylon’s discovery and pre-clinical pipeline programs - Dr. Thomas Hecht has joined Board of Directors
August 13, 2025
·
1 min read
Biotech Beach
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
Ensysce Biosciences, Inc. today announced the renewal of its collaboration with Quotient Sciences to undertake the study PF614-MPAR-102 to examine and evaluate the full commercial dose range of the PF614-MPAR drug product.
May 20, 2024
·
5 min read
Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics
Quotient Limited announced an agreement with Theradiag, a market leader in autoimmune disease testing and pioneer in theranostics, under which the two companies will partner to advance autoimmune diagnostics by leveraging Quotient’s MosaiQ platform.
June 8, 2022
·
7 min read
Policy
Quotient Limited Announces Intent to Voluntary Delist from the Nasdaq Global Market
Quotient Limited announced that it has given formal notice to the Nasdaq Stock Market LLC of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market.
December 12, 2022
·
3 min read
Business
Nanomerics Announces Quotient Sciences as its Clinical Trials Partner
Nanomerics Ltd., a private speciality pharmaceutical company, announced that the Company had signed an agreement with Quotient Sciences, a drug development and manufacturing accelerator, for the delivery of its Sunlight Trial.
March 28, 2022
·
4 min read
1 of 46,523
Next
